MetaVia Inc. (MTVA): Nasdaq/NYSE listing notice — MetaVia receives Nasdaq delisting notice for bid price below $1.00

MetaVia Inc.

Nasdaq notified MetaVia on May 29, 2025 that its closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until Nov 25, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, MetaVia may get an additional 180 days if it meets other listing standards; otherwise delisting may follow.
Company intends to monitor bid price and consider options, including a reverse stock split, to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

MetaVia Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 29, 2025, MetaVia Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of The Nasdaq Stock Market LLC ( “Nasdaq” ) informing the Company that because the closing bid price of the Company’s common stock listed on Nasdaq was below $1.00 per share for the prior 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Marke

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-054976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.